 |
|
Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults
A Randomized Equivalence Trial
Schlomo Staszewski, MD;
Philip Keiser, MD;
Julio Montaner, MD;
Francois Raffi, MD;
Joe Gathe, MD;
Vitor Brotas, MD;
Charles Hicks, MD;
Scott M. Hammer, MD;
David Cooper, MD;
Margaret Johnson, MD;
Stephanie Tortell, BSc;
Amy Cutrell, MS;
Daren Thorborn, PhD;
Robin Isaacs, MD;
Seth Hetherington, MD;
Helen Steel, MD;
William Spreen, PharmD;
for the CNAAB3005 International Study Team
JAMA. 2001;285:1155-1163.
Context Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor–containing regimen for initial antiretroviral treatment.
Objective To evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an indinavir-lamivudine-zidovudine regimen.
Design and Setting A multicenter, phase 3, randomized, double-blind trial with an enrollment period from August 1997 to June 1998, with follow-up through 48 weeks at 73 clinical research units in the United States, Canada, Australia, and Europe.
Patients Five hundred sixty-two antiretroviral-naive, HIV-infected adults with a plasma HIV RNA level of at least 10 000 copies/mL and a CD4 cell count of at least 100 x 106/L.
Interventions Patients were stratified by baseline HIV RNA level and randomly assigned to receive a combination tablet containing 150 mg of lamivudine and 300 mg of zidovudine twice daily plus either 300 mg of abacavir twice daily and indinavir placebo or 800 mg of indinavir every 8 hours daily plus abacavir placebo. After 16 weeks, patients with confirmed HIV RNA levels greater than 400 copies/mL were eligible to continue receiving randomized treatment or receive open-label therapy.
Main Outcome Measure Virologic suppression, defined as HIV RNA concentration of 400 copies/mL or less at week 48.
Results The proportion of patients who met the end point of having an HIV RNA level of 400 copies/mL or less at week 48 was equivalent in the abacavir group (51% [133/262]) and in the indinavir group (51% [136/265]) with a treatment difference of -0.6% (95% confidence interval [CI], -9% to 8%). In patients with baseline HIV RNA levels greater than 100 000 copies/mL, the proportion of patients achieving less than 50 copies/mL was greater in the indinavir group than in the abacavir group with 45% (45/100) vs 31% (30/96) and a treatment diference of -14% (95% CI, -27% to 0%). The 2 treatments were comparable with respect to their effects on CD4 cell count. There was no difference between groups in the frequency of treatment-limiting adverse events or laboratory abnormalities. One death in the abacavir group was attributed to hypersensitivity reaction, which occurred following rechallenge with abacavir, approximately 3 weeks after initiating study treatment.
Conclusions In this study of antiretroviral-naive HIV-infected adults, the triple nucleoside regimen of abacavir-lamivudine-zidovudine was equivalent to the regimen of indinavir-lamivudine-zidovudine in achieving a plasma HIV RNA level of less than 400 copies/mL at 48 weeks.
Author Affiliations: Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany (Dr Staszewski); University of Texas Southwestern Medical Center, and Department of Veterans Affairs, Dallas (Dr Keiser); St Paul's Hospital, Vancouver, British Columbia (Dr Montaner); CHRU de Nantes, Nantes, France (Dr Raffi); Houston Clinical Research Network, Division of Montrose Clinic, Houston, Tex (Dr Gathe); Servico Medicina 3, Hospital de Santo António dos Capuchos, Lisbon, Portugal (Dr Brotas); Duke University, Durham, NC (Dr Hicks); Beth Israel Deaconess Medical Center, Boston, Mass (Dr Hammer); St Vincent's Hospital, Sydney, Australia (Dr Cooper); Royal Free Hospital, London, England (Dr Johnson); Glaxo Wellcome Inc, Research Triangle Park, NC (Mss Tortell and Cutrell and Drs Hetherington, Steel, and Spreen); Merck & Co Inc, West Point, Pa (Dr Isaacs); and Glaxo Wellcome Research and Development, Greenford, Middlesex, England (Drs Thorborn and Steel).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLES
Scientific and Ethical Issues in Equivalence Trials
Benjamin Djulbegovic and Mike Clarke
JAMA. 2001;285(9):1206-1208.
EXTRACT
| FULL TEXT
March 7, 2001
JAMA. 2001;285(9):1229-1230.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review
Chowers et al.
J Antimicrob Chemother 2009;0:dkp191v1-dkp191.
ABSTRACT
| FULL TEXT
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal et al.
NEJM 2008;358:568-579.
ABSTRACT
| FULL TEXT
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio et al.
JAMA 2006;295:1152-1160.
ABSTRACT
| FULL TEXT
Overview of Antiretroviral Agents in 2005
Stanic and Schneider
Journal of Pharmacy Practice 2005;18:228-246.
ABSTRACT
Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Wainberg et al.
Antimicrob. Agents Chemother. 2005;49:1671-1678.
FULL TEXT
The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens
Arribas
J Antimicrob Chemother 2004;54:587-592.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial
Gallant et al.
JAMA 2004;292:191-201.
ABSTRACT
| FULL TEXT
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2004;292:251-265.
ABSTRACT
| FULL TEXT
Abacavir/Lamivudine/Zidovudine Continues to Be a Valid and Useful Antiretroviral Regimen
Shaefer
The Annals of Pharmacotherapy 2004;38:1314-1316.
FULL TEXT
Single-Class Therapy for HIV Is Not Optimal Care
Clay
The Annals of Pharmacotherapy 2004;38:1307-1309.
FULL TEXT
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
Gulick et al.
NEJM 2004;350:1850-1861.
ABSTRACT
| FULL TEXT
Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily
Yuen et al.
Antimicrob. Agents Chemother. 2004;48:176-182.
ABSTRACT
| FULL TEXT
Assessing the Validity of Published Randomized Controlled Trials in Podiatric Medical Journals
Turlik et al.
J. Am. Podiatr. Med. Assoc. 2003;93:392-398.
ABSTRACT
| FULL TEXT
Tuberculosis and HIV: A Partnership Against the Most Vulnerable
Cahn et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2003;2:106-123.
ABSTRACT
Thrombotic Thrombocytopenic Purpura Associated with Abacavir in a Patient with HIV Infection
Olszewski and Shapiro
J Intensive Care Med 2003;18:156-159.
ABSTRACT
Treatment of advanced HIV infection
Pulido and Arribas
J Antimicrob Chemother 2003;51:225-227.
FULL TEXT
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV
Dybul et al.
ANN INTERN MED 2002;137:381-433.
ABSTRACT
| FULL TEXT
Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial
Hammer et al.
JAMA 2002;288:169-180.
ABSTRACT
| FULL TEXT
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Yeni et al.
JAMA 2002;288:222-235.
ABSTRACT
| FULL TEXT
Lopinavir-Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley et al.
NEJM 2002;346:2039-2046.
ABSTRACT
| FULL TEXT
Abacavir vs. Indinavir
AIDS Clin Care 2001;2001:1-1.
FULL TEXT
Triple-Nucleoside Regimen Is a New Option for Initial HIV Treatment
JWatch Infect. Diseases 2001;2001:3-3.
FULL TEXT
Scientific and Ethical Issues in Equivalence Trials
Djulbegovic and Clarke
JAMA 2001;285:1206-1208.
FULL TEXT
|
